Losartan Potassium Tablet, Film Coated
Product Images NDC 72865-143

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 72865-143). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xlcare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100mg 1000s

Label for Losartan Potassium Tablets, USP 100 mg by XLCare Pharmaceuticals, Inc. The oral film-coated tablets come in a bottle containing 1000 tablets. The label includes storage instructions, a pharmacist dispensing note, and manufacturer information for XLCare Pharmaceuticals and Ascent Pharmaceuticals. It displays the NDC 72865-143-10 and the prescription-only designation.*

FDA Label Image

100mg 30s

Label for Losartan Potassium Tablets, USP 100 mg, film-coated oral tablets. The label shows the product is supplied in a bottle of 30 tablets, labeled for prescription use only. It is manufactured by XLCare Pharmaceuticals, Inc., with packaging details including storage instructions and warnings. The label includes an NDC number and states the tablet strength clearly.*

FDA Label Image

100mg 90s

Label for Losartan Potassium Tablets, USP 100 mg film-coated tablets by XLCare Pharmaceuticals, Inc. The label indicates a package containing 90 tablets, prescription only. It includes storage instructions, dosage guidance, manufacturer addresses, and a barcode. The label emphasizes no varnish on one area and features the NDC 72865-143-90.*

FDA Label Image

25mg 1000s

Label for Losartan Potassium Tablets, USP 25 mg film-coated tablets by XLCare Pharmaceuticals, Inc. The package contains 1000 tablets. The label includes storage instructions, dosage reference, barcode, and manufacturing information for XLCare Pharmaceuticals, Inc. and Ascent Pharmaceuticals, Inc.*

FDA Label Image

25mg 30s

Label for Losartan Potassium Tablets, USP 25 mg film-coated tablets by XLCare Pharmaceuticals, Inc. The package contains 30 tablets. The label includes storage instructions, warnings, and manufacturer information. It states the product is Rx only and provides the NDC 72865-141-30.*

FDA Label Image

25mg 90s

Losartan Potassium Tablets USP 25 mg film-coated tablets packaging label by XLCare Pharmaceuticals Inc. The label indicates 90 tablets per container with prescription status (Rx only). It includes storage instructions, warnings, and manufacturer details including Ascent Pharmaceuticals, Inc.*

FDA Label Image

50mg 1000s

Losartan Potassium Tablets, USP 50 mg film coated tablets label by XL Care Pharmaceuticals, Inc. The label indicates a package of 1000 tablets, prescription only. Storage instructions specify controlled room temperature. Additional manufacturing and warning information is included on the label.*

FDA Label Image

50mg 30s

Label for Losartan Potassium Tablets, USP 50 mg film-coated tablets by XLCare Pharmaceuticals, Inc. The label states 30 tablets per container, includes storage instructions, and cautions to keep out of reach of children. Manufactured by Ascent Pharmaceuticals, Inc. and XLCare Pharmaceuticals, Inc.*

FDA Label Image

50mg 90s

Label for Losartan Potassium 50 mg film-coated tablets by XLCare Pharmaceuticals, Inc. The label indicates a package containing 90 tablets, for oral use only, marked Rx only. It includes storage instructions and warnings, listing the manufacturer as Ascent Pharmaceuticals, Inc.*

FDA Label Image

Fig1

A line graph comparing the percentage of patients with the primary endpoint over 66 study months for Losartan Potassium and Atenolol. The graph shows a progressive increase for both, with Losartan Potassium exhibiting a slightly lower rate. It indicates an adjusted risk reduction of 13% (p=0.021).*

FDA Label Image

Fig2

A line graph comparing the percentage of patients with fatal or non-fatal stroke over time (in study months) between Losartan Potassium and Atenolol. The graph shows that Losartan Potassium is associated with a lower percentage of stroke cases, with an adjusted risk reduction of 25% (p=0.001). The x-axis represents study months up to 66, and the y-axis shows the percentage of affected patients up to 8%.*

FDA Label Image

Fig3

Figure 3 presents a forest plot illustrating primary endpoint events within demographic subgroups, comparing Losartan Potassium and Atenolol event rates for a primary composite outcome and stroke (fatal and non-fatal). It includes subgroups by age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD). Hazard ratios with 95% confidence intervals are shown, with sample size proportionate symbols plotted along a horizontal axis indicating favorability towards either Losartan Potassium or Atenolol.*

FDA Label Image

Fig4

A line graph comparing the percentage of patients with events over 48 months between Losartan Potassium and placebo groups. The x-axis represents time in months; the y-axis shows the percentage of patients with events. The graph indicates a 16.1% risk reduction associated with Losartan Potassium compared to placebo.*

FDA Label Image

Tab1

A table presenting the incidence of cough in two studies comparing HCTZ, Losartan, Lisinopril, and Placebo. Study 1 shows cough percentages for HCTZ (25%), Losartan (17%), and Lisinopril (69%). Study 2 compares Placebo (35%), Losartan (29%), and Lisinopril (62%). Demographic notes specify racial and gender distribution for each study.*

FDA Label Image

Tab2

A data table titled 'Pharmacokinetic Parameters in Hypertensive Adults and Children Age 6 to 16 Following Multiple Dosing.' It compares parameters such as AUC, Cmax, T1/2, Tpeak, and Clren for parent and active metabolite of Losartan Potassium in adults given 50 mg once daily for 7 days and children aged 6-16 given 0.7 mg/kg once daily for 7 days. Mean values with standard deviations or medians are presented.*

FDA Label Image

Tab3

A data table titled 'Table 3: Incidence of Primary Endpoint Events' comparing Losartan Potassium and Atenolol in terms of primary composite endpoint and its component events, as well as secondary endpoints, along with risk reduction, 95% confidence intervals, and p-values. The table includes event counts, rates per 1000 patient-years, and statistical significance values for cardiovascular outcomes during the study.*

FDA Label Image

Tab4

A data table titled 'Table 4: Incidence of Primary Endpoint Events,' comparing incidence, risk reduction, 95% confidence intervals, and p-values between Losartan and placebo groups for various clinical endpoints including primary composite endpoint, doubling of serum creatinine, ESRD, and death.*

FDA Label Image

Tab5

A data table titled 'Table 5: Efficacy Outcomes within Demographic Subgroups' presenting comparative outcomes for Losartan Potassium versus placebo. It details patient numbers, event rates for a primary composite endpoint, and ESRD event rates by demographic categories including overall results, age groups, gender, and race, along with hazard ratios and 95% confidence intervals.*

FDA Label Image

Struct

Chemical structure diagram of losartan potassium, showing its molecular arrangement including rings and functional groups, with potassium ion (K+) indicated.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.